GT200100238AA - SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS (FRACTIONARY APPLICATION # 1 DERIVED FROM LAPI-2001-0238) - Google Patents

SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS (FRACTIONARY APPLICATION # 1 DERIVED FROM LAPI-2001-0238)

Info

Publication number
GT200100238AA
GT200100238AA GT200100238AK GT200100238K GT200100238AA GT 200100238A A GT200100238A A GT 200100238AA GT 200100238A K GT200100238A K GT 200100238AK GT 200100238 K GT200100238 K GT 200100238K GT 200100238A A GT200100238A A GT 200100238AA
Authority
GT
Guatemala
Prior art keywords
osteoporosis
fractionary
lapi
receptor
derived
Prior art date
Application number
GT200100238AK
Other languages
Spanish (es)
Inventor
Kimberly O'keefe Cameron
Bruce Allen Lefker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100238AA publication Critical patent/GT200100238AA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A AGONISTAS DE PROTAGLANDINAS SELECTIVOS PARA EL RECEPTOR EP4. ESTA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENE ESOS COMPUESTOS, A PROCEDIMIENTOS DE TRATAMIENTO DE AFECCIONES QUE PRESENTAN BAJA MASA OSEA, PARTICULARMENTE OSTEOPOROSIS, FRAGILIDAD, UNA FRACTURA OSTEOPOROTICA, UN DEFECTO OSEO, PERDIDA DE HUESO IDIOPATICA INFANTIL, PERDIDA DE HUESO ALVEOLAR, PERDIDA DE HUESO MANDIBULAR, FRACTURA OSEA, OSTEOTOMIA, PERDIDA DE HUESO ASOCIADA CON PERIODONTITIS O ENCARNAMIENTO PROTESICO EN UN MAMIFERO.THIS INVENTION REFERS TO SELECTED PROTAGLANDIN AGONISTS FOR THE EP4 RECEIVER. THIS INVENTION ALSO REFERS TO PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, TO PROCESSING PROCESSES FOR AFFECTIONS THAT PRESENT LOW OSEA MASS, PARTICULARLY OSTEOPOROSIS, FRAGILITY, AN OSTEOPOROTIC BREAKING, PERIODIC DUTY HARD PERUTIOUS, PEREOUS PERDOLLAR, OF MANDIBULAR BONE, OSEA FRACTURE, OSTEOTOMY, LOSS OF BONE ASSOCIATED WITH PERIODONTITIS OR PROTESICAL INCARNATION IN A MAMMER.

GT200100238AK 2000-11-27 2001-11-27 SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS (FRACTIONARY APPLICATION # 1 DERIVED FROM LAPI-2001-0238) GT200100238AA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27

Publications (1)

Publication Number Publication Date
GT200100238AA true GT200100238AA (en) 2004-05-12

Family

ID=22959588

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200100238AK GT200100238AA (en) 2000-11-27 2001-11-27 SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS (FRACTIONARY APPLICATION # 1 DERIVED FROM LAPI-2001-0238)
GT200100238A GT200100238A (en) 2000-11-27 2001-11-27 SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT200100238A GT200100238A (en) 2000-11-27 2001-11-27 SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS.

Country Status (41)

Country Link
US (3) US6552067B2 (en)
EP (1) EP1339678B1 (en)
JP (2) JP3984164B2 (en)
KR (1) KR20030053063A (en)
CN (1) CN1476429A (en)
AR (1) AR035074A1 (en)
AT (1) ATE374182T1 (en)
AU (1) AU2002210848A1 (en)
BG (1) BG107697A (en)
BR (1) BR0115687A (en)
CA (1) CA2429850C (en)
CY (1) CY1106976T1 (en)
CZ (1) CZ20031257A3 (en)
DE (1) DE60130675T2 (en)
DK (1) DK1339678T3 (en)
EA (1) EA200300379A1 (en)
EC (1) ECSP034623A (en)
EE (1) EE200300246A (en)
ES (1) ES2291361T3 (en)
GT (2) GT200100238AA (en)
HN (1) HN2001000266A (en)
HU (1) HUP0400807A2 (en)
IL (1) IL155368A0 (en)
IS (1) IS6775A (en)
MA (1) MA26961A1 (en)
MX (1) MXPA03004623A (en)
NO (1) NO20032360L (en)
NZ (1) NZ525164A (en)
OA (1) OA12533A (en)
PA (1) PA8533901A1 (en)
PE (1) PE20020637A1 (en)
PL (1) PL362030A1 (en)
PT (1) PT1339678E (en)
SI (1) SI1339678T1 (en)
SK (1) SK5562003A3 (en)
SV (1) SV2003000746A (en)
TN (1) TNSN01166A1 (en)
TW (1) TW200424170A (en)
UY (1) UY27038A1 (en)
WO (1) WO2002042268A2 (en)
ZA (1) ZA200302803B (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60130675T2 (en) * 2000-11-27 2008-01-24 Pfizer Products Inc., Groton SELECTIVE AGONISTS OF THE EP4 RECEPTOR FOR THE TREATMENT OF OSTEOPOROSIS
EP1408961B1 (en) * 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
CA2451392A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
KR100826866B1 (en) 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2003211574A1 (en) 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
AU2003207900A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2003233729B2 (en) * 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
JP2005534653A (en) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 1,5-Disubstituted imidazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of ocular and bone diseases
JP4754820B2 (en) * 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム Gamma lactams and their use as prostaglandin agonists
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres comprising ONO-1301
AU2003275838A1 (en) * 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7528163B2 (en) 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006515015A (en) * 2003-01-10 2006-05-18 エフ．ホフマン−ラ　ロシュ　アーゲー 2-Piperidone derivatives as prostaglandin agonists
EP1586564B1 (en) * 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
WO2004078103A2 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2004261397A1 (en) 2003-07-18 2005-02-10 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
WO2005020917A2 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN102558231B (en) 2003-09-04 2015-05-27 默沙东公司 Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
US20070191319A1 (en) * 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
JP2008507521A (en) 2004-07-20 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド Ophthalmic composition for treating ocular hypertension
WO2006043655A1 (en) * 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
CA2585367A1 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
US7547685B2 (en) * 2004-11-08 2009-06-16 Allergan, Inc. Therapeutic substituted pyrrolidone compounds
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
CN101133037B (en) * 2005-01-27 2012-05-09 旭化成制药株式会社 6-membered heterocyclic compound and use thereof
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
CA2602535A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (en) * 2006-02-15 2006-07-19 (주)아이앤씨 Vertical type crusher for big sized waste mterial
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
US20100081631A1 (en) * 2006-12-18 2010-04-01 Guang Liang Jiang Methods and compositions for treating gastrointenstial disorders
EP2147672A4 (en) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine Cytotoxic t cell activator comprising ep4 agonist
SI2155733T1 (en) * 2007-05-23 2012-12-31 Allergan, Inc Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
EP2488168A1 (en) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Combination therapy treatment for viral infections
ES2593229T3 (en) * 2010-03-08 2016-12-07 Kaken Pharmaceutical Co., Ltd. New EP4 agonist
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
BR112013021035A2 (en) 2011-02-17 2016-10-11 Allergan Inc improved soft tissue replacement compositions and methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP3176162B1 (en) * 2012-07-19 2020-05-27 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
WO2014069401A1 (en) 2012-10-29 2014-05-08 株式会社カルディオ Pulmonary disease-specific therapeutic agent
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9914725B2 (en) 2013-03-15 2018-03-13 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
SG11201507470WA (en) 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (en) * 2013-07-19 2016-03-09 开曼化学股份有限公司 Methods, systems, and compositions for promoting bone growth
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP6449166B2 (en) 2013-10-15 2019-01-09 小野薬品工業株式会社 Drug-eluting stent graft
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
DK3152188T3 (en) 2014-06-06 2019-04-29 Allergan Inc UNKNOWN EP4 AGONISTS AS THERAPEUTIC RELATIONS
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
EP3307747A4 (en) 2015-06-12 2019-02-27 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
CN107011377B (en) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 A kind of preparation method of β-oxo-phosphoric acid ester
ES2929799T3 (en) 2017-12-25 2022-12-01 Asahi Kasei Pharma Corp Compounds containing 2-oxo-1,3,4-thiadiazinan-3-yl moiety with EP4 receptor agonist activity
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (en) * 1973-09-17 1975-04-03 Hoechst Ag NEW, NON NATURALLY OCCURRING ANALOGS OF PROSTANIC ACIDS AND THE PROCESS FOR THEIR PRODUCTION
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (en) 1975-04-28 1976-11-01 Syntex Inc PROCESS FOR THE PREPARATION OF 8-AZAPROSTAN ACID DERIVATIVES.
DE2528664A1 (en) 1975-06-27 1977-01-13 Hoechst Ag PYRROLIDONE AND THE METHOD FOR MANUFACTURING THEIR
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (en) 1976-05-04 1977-11-17 Hoechst Ag PYRROLIDONE AND THE METHOD FOR MANUFACTURING THEIR
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (en) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (en) 1993-07-06 1993-07-06 Ab Astra NEW COMPOUNDS
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
WO2000021532A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
EE200200355A (en) * 1999-12-22 2003-10-15 Pfizer Products Inc. EP4 receptor selective agonists for the treatment of osteoporosis
ATE327751T1 (en) * 2000-01-31 2006-06-15 Pfizer Prod Inc USE OF PROSTAGLAND RECEPTOR 4 ACTIVATORS FOR THE TREATMENT OF ACUTE OR CHRONIC RENAL INSUFFICIENCY
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
DE60130675T2 (en) * 2000-11-27 2008-01-24 Pfizer Products Inc., Groton SELECTIVE AGONISTS OF THE EP4 RECEPTOR FOR THE TREATMENT OF OSTEOPOROSIS
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
CA2429850A1 (en) 2002-05-30
EE200300246A (en) 2003-10-15
EA200300379A1 (en) 2003-08-28
MXPA03004623A (en) 2003-09-05
NO20032360L (en) 2003-07-23
DK1339678T3 (en) 2008-02-04
US6552067B2 (en) 2003-04-22
BR0115687A (en) 2003-09-09
JP2004521869A (en) 2004-07-22
WO2002042268A2 (en) 2002-05-30
NZ525164A (en) 2005-04-29
CA2429850C (en) 2008-12-30
ECSP034623A (en) 2003-07-25
PL362030A1 (en) 2004-10-18
EP1339678B1 (en) 2007-09-26
DE60130675T2 (en) 2008-01-24
WO2002042268A3 (en) 2002-07-25
SV2003000746A (en) 2003-01-13
TNSN01166A1 (en) 2005-11-10
US7192979B2 (en) 2007-03-20
US20030149086A1 (en) 2003-08-07
BG107697A (en) 2004-01-30
TW200424170A (en) 2004-11-16
OA12533A (en) 2006-06-05
CZ20031257A3 (en) 2004-04-14
JP2007197467A (en) 2007-08-09
PE20020637A1 (en) 2002-07-18
SI1339678T1 (en) 2007-12-31
CY1106976T1 (en) 2012-09-26
IL155368A0 (en) 2003-11-23
PT1339678E (en) 2007-11-30
US6747054B2 (en) 2004-06-08
GT200100238A (en) 2002-06-26
EP1339678A2 (en) 2003-09-03
ATE374182T1 (en) 2007-10-15
PA8533901A1 (en) 2002-11-28
DE60130675D1 (en) 2007-11-08
KR20030053063A (en) 2003-06-27
HN2001000266A (en) 2002-01-30
HUP0400807A2 (en) 2004-07-28
CN1476429A (en) 2004-02-18
AR035074A1 (en) 2004-04-14
AU2002210848A1 (en) 2002-06-03
ES2291361T3 (en) 2008-03-01
SK5562003A3 (en) 2004-08-03
MA26961A1 (en) 2004-12-20
UY27038A1 (en) 2002-07-31
IS6775A (en) 2003-04-10
ZA200302803B (en) 2004-04-13
JP3984164B2 (en) 2007-10-03
NO20032360D0 (en) 2003-05-26
US20020065308A1 (en) 2002-05-30
US20040259921A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
GT200100238AA (en) SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS (FRACTIONARY APPLICATION # 1 DERIVED FROM LAPI-2001-0238)
CR6678A (en) SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS
CO4910163A1 (en) PREVENTION OF THE LOSS AND RESTORATION OF THE BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS
BR0308208A (en) Compound, pharmaceutical composition, process for preparing a pharmaceutical composition, methods for inhibiting cathepsin activity in a mammal in need thereof, for treating or preventing a disease, for treating cathepsin-dependent conditions in a mammal in need thereof, for inhibiting bone resorption, to increase bone mineral density, and to reduce the risk of fractures
BR0100381A (en) Treatment of osteoporosis with ep / 2 / ep4 receptor agonistasselectants
NO20040331L (en) Medicines for diseases with bone loss that have Eragonist as the active ingredient
AR060409A1 (en) GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE THE OSEA MASS AND TO TREAT OSTEOPOROSIS AND OTHER AFFECTIONS CHARACTERIZED BY LOW OSEA MASS AND COMBINED THERAPY RELATED TO THESE AGONISTS
BR0111210A (en) Composition for the treatment and / or prevention of osteoporosis and / or inflammatory joint disease
SE9901272D0 (en) New improved formulation
PA8452701A1 (en) PROSTAGLANDIN AGONISTS
BR0310087A (en) Hyaluronic acid injectable solid carriers for application of osteogenic proteins
AR040695A1 (en) LACTOFERRINE POLYPEPTIDE TO IMPROVE OSEA HEALTH
BR0203388A (en) Endoparasiticide Gel Composition
BR9911917A (en) Compositions comprising gaba and caffeine analogs
DE60225143D1 (en) SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OR PROPHYLAXIS OF DIABETES
BR0203267A (en) Pharmaceutical combinations for the treatment of neurodegenerative diseases
AU2003251728A1 (en) Placental growth factor as a target for the treatment of osteoporosis
CR6952A (en) SELECTIVE AGONISTS OF THE EP4 RECEPTOR IN THE TREATMENT OF OSTEOPOROSIS
GB0422929D0 (en) Bioactive vitamin D analogues
ECSP972347A (en) PREVENTION OF LOSS AND RESTORATION OF THE BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS
UY26651A1 (en) COMBINED THERAPY FOR OSTEOPOROSIS
ECSP982698A (en) PROSTAGLANDIN AGONISTS
ECSP982554A (en) PROSTAGLANDIN AGONISTS
AR019492A1 (en) PHARMACEUTICAL COMPOSITIONS OF CONTROLLED LIBERATION